Steven Rosenberg

Dr. Steven Rosenberg is the pioneering scientist who first demonstrated that tumor-infiltrating lymphocytes could mediate tumor regression in humans, founding the field of TIL therapy. His decades of work at the NCI established the principles of TIL isolation, expansion, and adoptive transfer that underpin current clinical TIL products including lifileucel. He is the most cited figure in the history of TIL-based cancer immunotherapy.